Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 2, 2010, Pages 189-194

  D'Arca, Domenico ^a,b   LeNoir, James ^a   Wildemore, Bernadette ^a   Gottardo, Fedra ^a   Bragantini, Emma ^a   Shupp Byrne, Dolores ^a   Zanesi, Nicola ^c   Fassan, Matteo ^a   Croce, Carlo M ^c   Gomella, Leonard G ^a   Baffa, Raffaele ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Cox 2; FHIT; Knock out mouse; Rofecoxib; Urinary bladder cancer

Indexed keywords

DRINKING WATER; FRAGILE HISTIDINE TRIAD PROTEIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; GENETIC DISORDER; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACID ANHYDRIDE HYDROLASES; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; LACTONES; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; SULFONES; URINARY BLADDER NEOPLASMS;

EID: 77249121207     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.01.016     Document Type: Article

References (35)

1. Kelloff G.J., Boone C.W., Crowell J.A., et al. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 3 (1994) 85-98
2. Pereg D., and Lishner M. Nonsteroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258 (2005) 115-123
3. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
4. Ziegler J. Early trials probe COX-2 inhibitors' cancer-fighting potential. J Natl Cancer Inst 91 (1999) 1186-1187
5. Chandrasekharan N.V., Dai H., Roos K.L.T., et al. COX-3 a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS 99 (2002) 13926-13931
6. Steele V.E., Hawk E.T., Viner J.L., et al. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523/4 (2003) 137-144
7. Chan C.C., Boyce S., Brideau C., et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor pharmacological and biochemical profiles. J Pharmacol Exp Ther 290 (1999) 551-560
8. Masferrer J.L., Isakson P.C., and Seibert K. Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 25 (1996) 363-372
9. Soslow R.A., Dannenberg A.J., Rush D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
10. Fischer S.M., Lo H.H., Gordon G.B., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25 (1999) 231-240
11. Tucker O.N., Dannenberg A.J., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
12. Ristimaki A., Honkanen N., Jankala H., et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57 (1997) 1276-1280
13. Pruthi R.S., Derksen E., Gaston K., et al. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology 64 (2004) 637-642
14. Gurocak S., Sozen S., Erdem O., et al. Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder. Urol Int 76 (2006) 51-56
15. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6 (2000) 2424-2430
16. Wadhwa P., Goswami A.K., Joshi K., et al. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 37 (2005) 47-53
17. Kim S.I., Kwon S.M., Kim Y.S., and Hong S.J. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60 (2002) 816-821
18. Kitayama W., Denda A., Okajima E., et al. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis 20 (1999) 2305-2310
19. Hattori K., Iida K., Joraku A., et al. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 97 (2006) 640-643
20. Grubbs C.J., Lubet R.A., Koki A.T., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60 (2000) 5599-5602
21. Okajima E., Denda A., Ozono S., et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 58 (1998) 3028-3031
22. Lubet R.A., Huebner K., Fong L.Y., et al. 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: Characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis 26 (2005) 571-578
23. Vecchione A., Sevignani C., Giarnieri E., et al. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 10 (2004) 7607-7612
24. Ohta M., Inoue H., Cotticelli M.G., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
25. Baffa R., Gomella L.G., Vecchione A., et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 156 (2000) 419-424
26. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
27. Baffa R., Letko J., McClung C., et al. Molecular genetics of bladder cancer: Targets for diagnosis and therapy. J Exp Clin Cancer Res 25 (2006) 145-160
28. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM 343 (2000) 1520-1528
29. Iliopoulos D., Guler G., Han S.Y., et al. Fragile genes as biomarkers: Epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24 (2005) 1625-1633
30. Ristimaki A., Nieminen O., Saukkonen K., et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158 (2001) 849-853
31. Hilmy M., Campbell R., Bartlett J.M., et al. The relationship between the systemic inflammatory response, tumor proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 95 (2006) 1234-1238
32. Skopelitou A.S., Gloustianou G., Bai M., et al. FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo 15 (2001) 169-173
33. Gutiérrez M.I., Siraj A.K., Khaled H., et al. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol 17 (2004) 1268-1274
34. Dumon K.R., Ishii H., Fong L.Y., et al. FHIT gene therapy prevents tumor development in FHIT-deficient mice. Proc Natl Acad Sci USA 98 (2001) 3346-3351
35. Fong L.Y., Fidanza V., Zanesi N., et al. Muir-Torre-like syndrome in FHIT-deficient mice. Proc Natl Acad Sci USA 97 (2000) 4742-4747